Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · IEX Real-Time Price · USD
1.210
+0.020 (1.68%)
At close: Feb 26, 2024, 4:00 PM
1.250
+0.040 (3.31%)
After-hours: Feb 26, 2024, 7:59 PM EST
1.68%
Market Cap 85.71M
Revenue (ttm) 21.43M
Net Income (ttm) -114.63M
Shares Out 70.84M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 860,880
Open 1.220
Previous Close 1.190
Day's Range 1.200 - 1.250
52-Week Range 0.590 - 12.930
Beta 0.22
Analysts Buy
Price Target 14.67 (+1,112.4%)
Earnings Date Mar 5, 2024

About ACRS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumat... [Read more]

Sector Healthcare
IPO Date Oct 7, 2015
Employees 100
Stock Exchange NASDAQ
Ticker Symbol ACRS
Full Company Profile

Financial Performance

In 2022, ACRS's revenue was $29.75 million, an increase of 340.05% compared to the previous year's $6.76 million. Losses were -$86.91 million, -4.35% less than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is $14.67, which is an increase of 1,112.40% from the latest price.

Price Target
$14.67
(1,112.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was W...

6 weeks ago - GlobeNewsWire

Aclaris Therapeutics Provides Corporate Update

- ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce -

2 months ago - GlobeNewsWire

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, ...

2 months ago - GlobeNewsWire

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial.

3 months ago - Reuters

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Web...

3 months ago - GlobeNewsWire

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Toplin...

4 months ago - GlobeNewsWire

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing no...

5 months ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...

5 months ago - GlobeNewsWire

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases –

5 months ago - GlobeNewsWire

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 -

7 months ago - GlobeNewsWire

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel dr...

9 months ago - GlobeNewsWire

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

WAYNE, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

9 months ago - GlobeNewsWire

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

- Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on...

10 months ago - GlobeNewsWire

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d...

10 months ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Provides 2023 Outlook

WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Announces Key Leadership Transitions

- Dr. Neal Walker to transition to Chair of the Board of Directors

1 year ago - GlobeNewsWire

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

- Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023

1 year ago - GlobeNewsWire

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...

1 year ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

1 year ago - GlobeNewsWire